COVAXIN to be ready by Februarytext_fields
New Delhi: The indigenous vaccine named COVAXIN developed by Bharat Biotech in partnership with Indian Council of Medical Research (ICMR) is to be launched in February, reported Reuters. The vaccine which has been found to be safe in its Phase 1 and 2 is currently in phase 3 human trials.
A senior scientist informed the news agency that the vaccine has shown good efficacy and is expected to be made available by February. However, the vaccine innovator Bharat Biotech has not yet responded to this news.
The SARS-CoV-2 strain isolated by National Institute of Virology, Pune from the novel Coronavirus is used to study and manufacture the vaccine by Bharat biotech, Hyderabad.
After assessing the data of Phase 1 and 2, Drug Controller General of India (DCGI) had approved the vaccine for phase three clinical trials. Around 28,500 people including medical staffs have enrolled for phase 3 clinical trials.